Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-TYRP1/CD3 T-cell engager RO7293583

A bispecific T-cell engager directed against the tumor-associated antigen (TAA) tyrosinase-related protein 1 (TYRP1; TRP1; glycoprotein 75; gp75) and the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-TYRP1/CD3 T-cell engager RO7293583 binds to both CD3 on cytotoxic T lymphocytes (CTLs) and TYRP1 found on TYRP1-expressing tumor cells. This activates and redirects CTLs to TYRP1-expressing tumor cells, which results in the CTL-mediated death of TYRP1-expressing tumor cells. TYRP1, a transmembrane glycoprotein, is involved in melanin biosynthesis and is expressed in melanosomes of human melanocytes and melanomas.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-gp75/CD3 T-cell engager RO7293583
anti-TRP1/CD3 T-cell engager RO7293583
TYRP1-targeting CD3 T-cell engager RO7293583
Code name:RO 7293583
RO-7293583
RO7293583
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search